First launch for Ipsen's six-month Decapeptyl for prostate cancer
This article was originally published in Scrip
Executive Summary
Ipsen/Debiopharm's six-month sustained release formulation of Decapeptyl (triptorelin embonate 22.5 mg) has been launched in France, its first country, for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.